Drug profile · INN
grepafloxacin hydrochloride
RAXAR
grepafloxacin hydrochloride (RAXAR) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — grepafloxacin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
grepafloxacin hydrochloride (RAXAR) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA gyrase inhibitor
Primary target: DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is grepafloxacin hydrochloride?
grepafloxacin hydrochloride (RAXAR) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for grepafloxacin hydrochloride?
RAXAR is a marketed brand name for grepafloxacin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of grepafloxacin hydrochloride?
grepafloxacin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.